NICE Recommends Boston Scientific Defibrillators

The UK’s National Institute for Health and Care Excellence (NICE) issued guidance recommending the use of Boston Scientific’s cardiac resynchronization therapy defibrillators (CRT-D) for treating patients with heart failure.

The device is designed to extend battery life of the CRT-Ds, which are used as a treatment option for heart failure and life-threatening ventricular arrhythmias.

The device uses a lithium manganese dioxide battery, which is claimed to be less susceptible to the variations in voltage and resistance associated with early battery depletion.

The NICE medical technologies advisory committee found the evidence from 16 independent clinical and economic studies supported a case for adoption and concluded that EnduraLife-powered CRT-Ds have a greater battery capacity and longer battery life compared with other CRT-Ds reviewed.